

QUANTITATIVE IMAGING WORKSHOP XXI:

Advancing Routine Clinical Use of Health Information
from Thoracic CT Screening for Public Health

November 14 – 15, 2024 • Virtual

WORKSHOP OVERVIEW

The goal of the twenty-first annual **Quantitative Imaging Workshop (QIW)**, brought to you by the Prevent Cancer Foundation in partnership with the American Lung Association, is to continue to accelerate uptake of annual chest CT screening in eligible current and former smokers. All sessions of the 2024 Workshop relate to the goal of increasing participation in annual CT screening to preempt the lethality of major chest diseases.

Professor Matthijs Oudkerk will present the keynote address on the status of chest CT imaging for detecting and managing coronary artery calcium within the thoracic CT setting. The need to validate imaging changes for coronary calcium dynamically will be discussed. Current coronary calcium imaging is focused on one-time risk analysis and more work is needed to define methods to detect biological changes over serial imaging timepoints along with other methodological refinements to better evaluate coronary endpoints within the lung cancer screening encounter.

The interactive discussion segments of **QIW XXI** will explore critical barriers to clinical and administrative workflows that impede the rate of national scaling of low-dose computed tomography (LDCT) screening. Additional issues surrounding the integration of artificial intelligence tools and potential best practice solutions will be discussed. A key focus area for discussion will center on the challenges with acquiring appropriate screening cases where clinical outcomes are known. As recently highlighted in the New York Times, this is the single greatest threat to robust development of these promising computational tools. Faculty with experience in developing solutions in this area will participate in an engaging panel discussion format.

The two breakout topics for **QIW XXI** will include:

- First, the multi-disciplinary evaluation of the mismatch with existing single disease-based care delivery and the potential for transformational tools such as thoracic CT to inform the prevention of multiple disease states requiring a more holistic screening participant encounter.
- Second, further exploration into using quantitative tools to characterize dynamic changes in pulmonary diseases such as emphysema which is frequently detected during lung cancer screening. Currently there are limited pharmacological options for pulmonary disease but with emerging quantitative biomarkers, innovative drug trial designs are now possible for early changes seen with the development of pulmonary diseases.

Throughout the **Quantitative Imaging Workshop**, important solutions to address chest screening implementation bottlenecks will be enumerated to focus further discussion on defining discrete action plans to improve the screening process in the upcoming year.

Registration for this critical Zoom-accessible forum is free of charge.

For additional information and Workshop registration, visit the **QIW XXI** website.